Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

(2021) Maryam Mukhamedova et al.   IMMUNITY

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

(2021) Tracy J Ruckwardt et al.   Lancet Respiratory Medicine

Hospitalisation, morbidity and outcomes associated with respiratory syncytial virus compared with influenza in adults of all ages

(2021) Benjamin Andrew Leaver et al.   Influenza and Other Respiratory Viruses

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine

(2021) Edward E Walsh et al.   JOURNAL OF INFECTIOUS DISEASES

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

(2020) Kristi Williams et al.   JOURNAL OF INFECTIOUS DISEASES

Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

(2020) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

(2020) M. Pamela Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination

(2020) Carl W. Davis et al.   SCIENCE

Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study

(2019) Geert Leroux-Roels et al.   VACCINE

A proof of concept for structure-based vaccine design targeting RSV in humans

(2019) Michelle C. Crank et al.   SCIENCE

Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination

(2019) Anna-Karin E. Palm et al.   Frontiers in Immunology

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate

(2019) Beate Schmoele-Thoma et al.   Open Forum Infectious Diseases

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

(2018) Natalie I Mazur et al.   LANCET INFECTIOUS DISEASES

Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

(2018) Joseph B. Domachowske et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

(2017) Judith Falloon et al.   JOURNAL OF INFECTIOUS DISEASES

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

(2017) Ting Shi et al.   LANCET

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein

(2017) Michael B. Battles et al.   Nature Communications

Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus

(2017) Xiaolin Wen et al.   Nature Microbiology

Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination

(2016) Ali H Ellebedy et al.   NATURE IMMUNOLOGY

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

(2015) Joan O. Ngwuta et al.   Science Translational Medicine

Kinetics of the Neutralizing Antibody Response to Respiratory Syncytial Virus Infections in a Birth Cohort

(2013) C.J. Sande et al.   JOURNAL OF MEDICAL VIROLOGY

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

(2013) Davide Corti et al.   NATURE

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

(2013) J. S. McLellan et al.   SCIENCE

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

(2012) M. Magro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

(2011) J. S. McLellan et al.   JOURNAL OF VIROLOGY

Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F

(2010) J. S. McLellan et al.   JOURNAL OF VIROLOGY